Alnylam Files Application for Vutrisiran to Treat ATTR Amyloidosis
Alnylam Pharmaceuticals, Inc. has submitted a Type II variation application to the European Medicines Agency (EMA) for vutrisiran, an investigational RNA interference (RNAi) therapy aimed at treating ATTR amyloidosis with cardiomyopathy (ATTR-CM). This application is based on the positive results…